Reactions 1680, p67 - 2 Dec 2017 Varicella zoster virus vasculitis and pneumocystis pneumonia: 2 case reports In a retrospective case control study, two patients [ages not stated; not all sexes stated] were described, who developed varicella zoster virus (VZV) vasculitis and pneumocystis pneumonia each, during treatment with belatacept. The woman who developed VZV vasculitis, died after two months. The patients were switched from calcineurin inhibitors to IV belatacept 5 mg/kg for improved survival following kidney allograft. Belatacept was administered on days 1, 15, 29, 43, 57 and for 28 days thereafter. Sixteen months later, one woman developed cerebral VZV vasculitis, and her belatacept was discontinued. She died of vasculitis, 2 months following belatacept discontinuation. Another patient developed pneumocystis pneumonia 17 months after switching to belatacept and hence, it was discontinued. The patient experienced a graft loss 6 months after belatacept discontinuation [not all outcomes stated]. Author comment: "We reported 2 very serious infectious adverse events, and in one case the patient died from a very rare cerebral VZV complication. . .but larger cohorts are required to evaluate the risks of belatacept used as a rescue strategy." Bertrand D, et al. Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study. American Journal of Transplantation 17: 2937-2944, No. 11, Nov 2017. Available from: URL: http:// doi.org/10.1111/ajt.14427 - France 803284155 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera